Premium
Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis
Author(s) -
Shiozawa Yusuke,
McGee Samantha,
Pienta Michael J.,
McGregor Natalie,
Jung Younghun,
Yumoto Kenji,
Wang Jingcheng,
Berry Janice E.,
Pienta Kenneth J.,
Taichman Russell S.
Publication year - 2013
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.24592
Subject(s) - prostate cancer , bone metastasis , erythropoietin , metastasis , oncology , cancer research , medicine , cancer
Erythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing chemotherapy by reducing fatigue and the need for transfusions. However, several meta‐analyses have revealed that Epo treatments are associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression, using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances metastasis. Together, these findings suggest that Epo may be useful for treating severe anemia in PCa patients without increasing metastatic risk. J. Cell. Biochem. 114: 2471–2478, 2013. © 2013 Wiley Periodicals, Inc.